Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin and Celecoxib in Prostate Cancer with Rising PSA
NCT01220973Phase 2Completed
- Sponsor
- Rutgers University
- Start
- Feb 2009
- Primary completion
- Nov 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atorvastatin and celecoxib in prostate cancer (PCa), sponsored by Rutgers University. Primary endpoint: Prostate-Specific Antigen Response at 6 months. Started Feb 2009; status: completed.
02
Drugs
atorvastatincelecoxib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01220973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01220973.